Twenty-four-hour and office blood pressure measurement in a comprehensive assessment of the effectiveness of 12-week therapy with a triple fixed-dose combination of amlodipine/indapamide/perindopril in hypertensive patients in actual clinical practice

Aim. To study the efficacy and safety of the triple fixed-dose combination (FDC) of amlodipine/indapamide/perindopril on blood pressure (BP) profile in patients with grade I-II hypertension (HTN) in actual clinical practice.

Material and methods. Data from 54 patients with paired 24-hour ambulatory BP monitoring (ABPM) data were included in the TRICOLOR subanalysis (ClinicalTrials. gov study ID — NCT03722524). The mean 24-hour, daytime, and nighttime BP were calculated at baseline and after 12-week follow-up. We determined the proportion of patients with nocturnal HTN (≥120/70 mm Hg) and nocturnal hypotension (<100/60 and <90/50 mm Hg) initially and after 12 weeks of triple FDC therapy. Patients with nocturnal BP decrease included dippers (D; 10-20%), reduced dippers (RD; 0-10%) and extreme dippers (ED; >20%), as well as those without nocturnal BP decrease (>0%, non-dipper (ND)). The smoothness index (SI) was analyzed as the ratio of the mean hourly SBP fall to its mean standard deviation in paired ABPM. To assess the BP phenotypes, two methods were used with reference values of <130/80 and <140/90 mm Hg for ABPM and office BP, respectively. Controlled hypertension (CHT), uncontrolled hypertension (UHT), white coat hypertension (WHT) and masked ineffectiveness of antihypertensive therapy were distinguished.

Results. Among 1247 participants of the TRICOLOR study, 54 patients with valid paired ABPM were selected (men, 46%; mean age, 57,7 [12,1] years; mean office BP, 150,4 [16,6]/93,3 [10,7] mm Hg; HTN duration, 8,3 [7,5] years). Initially, the mean 24-hour, daytime and nighttime BP was 141,1 [15,4]/85,9 [9,9], 144,2 [15,5]/88,8 [10,5] and 132,6 [18,0]/78,1 [9,9] mm Hg, respectively. After 12-week follow-up, the mean 24-hour, daytime and nighttime BP was 123,1 [10,5]/75,6 [8,5], 125,7 [10,9]/77,9 [8,7] and 115,4 [10,2]/68,6 [8,8] mm Hg, respectively (p<0,001). After 12-week follow-up, the proportion of patients with nocturnal hypertension decreased from 64,8% to 25,0% (2,6 times) (p<0,001). The proportion of NDs and EDs decreased from 16,7% and 7,4% to 5,8% and 0%, respectively (p=0,048); the proportion of patients with RD and D patterns increased from 42,6% and 33,3 to 57,7% and 36,5%, respectively (p=0,048). With triple FDC therapy, the SI during the day was higher than 0,73 in half of the cases. According to the two methods, the proportion of patients with UHT decreased from 81,6% to 4,4%, WHT from 12,2% to 0%. The prevalence of CHT increased from 4,1% to 57,8%, while masked ineffectiveness of antihypertensive therapy — from 2,0% to 37,8%.

Conclusion. Twelve-week FDC therapy of amlodipine/indapamide/perindopril led to a significant fall in the mean 24-hour, daytime and nighttime BP values. Comprehensive analysis of two techniques (24-hour and office BP measurement) identified patients requiring further triple FGC titration.

1. Parati G, Lombardi C, Pengo M, et al. Current challenges for hypertension management: From better hypertension diagnosis to improved patients’ adherence and blood pressure control. Int J Cardiol. 2021;331:262-9. doi:10.1016/j.ijcard.2021.01.070.

2. Boytsov SA, Balanova YuA, Shalnova SA. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. by the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) doi:10.15829/1728-8800-2014-4-4-14.

3. Obara T, Ohkubo T, Kikuya M, et al. J-HOME Study Group. Prevalence of masked uncontrolled and treated white-coat hypertension defined according to the average of morning and evening home blood pressure value: from the Japan Home versus Office Measurement Evaluation Study. Blood Press Monit. 2005;10(6):311-6. doi:10.1097/00126097-200512000-00005.

4. Platonova E, Deev A, Gorbunov V, et al. EP000322 Comparative evaluation of prevalence of hypertensive phenotypes by using home and office blood pressure measurements in treated and untreated subjects ≥55 ages. International Journal of Cardiology. 2009;137:S56. doi:10.1016/j.ijcard.2009.09.186.

5. Banegas JR, Ruilope LM, de la Sierra A, et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J. 2014;35(46):3304-12. doi:10.1093/eurheartj/ehu016.

6. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.

7. Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.

8. Düsing R, Waeber B, Destro, M, et al. Triple-combination therapy in the treatment of hypertension: a review of the evidence. J Hum Hypertens. 2017;31:501-10. doi:10.1038/jhh.2017.5.

9. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause‐specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55-61. doi:10.1161/HYPERTENSIONAHA.107.100727.

10. Fan H-Q, Li Y, Thijs L, et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens. 2010;28(10):2036-45. doi:10.1097/HJH.0b013e32833b49fe.

11. Yano Y, Kario K. Nocturnal blood pressure and cardiovascular disease: a review of recent advances. Hypertens Res. 2012;35(7):695-701. doi:10.1038/hr.2012.26.

12. Li Y, Wang JG. Isolated nocturnal hypertension: a disease masked in the dark. Hypertension. 2013;61(2):278-83. doi:10.1161/HYPERTENSIONAHA.111.00217.

13. Yang WY, Melgarejo JD, Thijs L, et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA. 2019;322(5):409-420. doi:10.1001/jama.2019.9811.

14. Wang C, Li Y, Zhang J, et al. Prognostic effect of isolated nocturnal hypertension in chinese patients with nondialysis chronic kidney disease. J Am Heart Assoc. 2016;5(10):e004198. doi:10.1161/JAHA.116.004198.

15. Parati G, Ochoa JE, Lombardi C, et al. Assessment and management of blood pressure variability. Nat Rev Cardiol. 2013;10(3):143-55. doi:10.1038/nrcardio.2013.1.

16. Parati G, Stergiou G, O’Brien et al. European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359-66. doi:10.1097/HJH.0000000000000221.

17. Mourad JJ, Amodeo C, de Champvallins M, et al.; study coordinators, investigators. Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine singlepill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial. J Hypertens. 2017;35(7):1481-95. doi:10.1097/HJH.0000000000001359.

18. Kario K. Essential manual of 24 Hour Blood Pressure Management: From morning to nocturnal hypertension. John Wiley & Sons, Ltd. 2015. ISBN:9781119087243. doi:10.1002/9781119087281.

19. Mallion JM, Chamontin B, Asmar R, et al.; REASON Project. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study. Am J Hypertens. 2004;17(3):245-51. doi:10.1016/j.amjhyper.2003.11.001.

20. Parati G, Schumacher H, Bilo G, et al. Evaluating 24-h antihypertensive efficacy by the smoothness index: A meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens. 2010;28:2177-83. doi:10.1097/HJH.0b013e32833e1150.

21. Karpov YuA, Gorbunov VM, Logunova NA. Triple fixed-dose combination in the treatment of hypertension: the results of the Russian observational study TRICOLOR. Russian Journal of Cardiology. 2020;25(10):4130. (In Russ.) doi:10.15829/1560-4071-2020-4130.

22. Parati G, Omboni S, Rizzoni D, et al. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16(11):1685-91. doi:10.1097/00004872-199816110-00016.

23. Gorbunov V, Oganov R, Deev A. Comparative informativeness of various methods of analyzing the results of daily blood pressure monitoring in assessing the effectiveness of antihypertensive therapy. Cardiovascular Therapy and Prevention. 2003,2(1):17-25. (In Russ.)

24. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. The Dublin outcome study. Hypertension. 2005;46:156-61. doi:10.1161/01.HYP.0000170138.56903.7a.

25. Páll D, Szántó I, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig. 2014;34(10):701-8. doi:10.1007/s40261-014-0223-0.

26. Tóth K; PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/ indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137-45. doi:10.1007/s40256-014-0067-2. Erratum in: Am J Cardiovasc Drugs. 2014;14(3):239.

27. Fujiwara Т, Hoshide S, Tomitani N, et al. Clinical significance of nocturnal home blood pressure monitoring and nocturnal hypertension in asia J Clin Hypertens. 2021;00:1-10. doi:10.1111/jch.14218.

28. Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al., for the Hygia Project Investigators, Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. European Heart Journal. 2020;41(48):4565-76. doi:10.1093/eurheartj/ehz754.

29. Omboni S, Parati G, Palatini P, et al. Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation. J Hypertens. 1998;16(6):733-8. doi:10.1097/00004872-199816060-00003.

30. Wang C, Deng WJ, Gong WY, et al. Nocturnal hypertension correlates better with target organ damage in patients with chronic kidney disease than a nondipping pattern. The Journal of Clinical Hypertension. 2015;17(10):792-801. doi:10.1111/jch.12589.